Co-Authors
This is a "connection" page, showing publications co-authored by DAVID SANGHYUN HONG and MICHAEL CURRAN.
Connection Strength
1.600
-
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 2024 Jan 09; 9(1).
Score: 0.245
-
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro Oncol. 2023 08 03; 25(8):1415-1427.
Score: 0.238
-
Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
Score: 0.226
-
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res. 2021 06 01; 27(11):3050-3060.
Score: 0.202
-
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380.
Score: 0.195
-
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer. 2019 11 26; 7(1):323.
Score: 0.184
-
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. Clin Cancer Res. 2018 03 01; 24(5):1138-1151.
Score: 0.162
-
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
Score: 0.148